丁苯酞软胶囊治疗豆纹动脉穿支动脉粥样硬化性疾病型梗死疗效观察

Curative effect of butylphthalide soft capsule in the treatment of infarction classified as branch atheromatous disease involving the lenticulostriate artery territory

目的研究丁苯酞软胶囊治疗豆纹动脉(LSA)穿支动脉粥样硬化性疾病(BAD)型梗死的临床疗效。方法选取2017年6月至2020年6月中山市小榄人民医院神经内科诊治的68例LSA-BAD型梗死患者作为研究对象。根据随机单双数法将所有患者分为观察组和对照组各34例。对照组患者给予常规治疗,观察组患者在对照组常规治疗的基础上给予丁苯酞软胶囊治疗。治疗14 d后,比较两组患者的临床疗效及治疗前后的美国国立卫生研究院卒中量表(NIHSS)评分和日常生活能力量表(ADL)评分,并比较两组患者的不良反应发生情况。结果观察组患者的治疗总有效率为94.12%,明显高于对照组的70.59%,差异有统计学意义(P<0.05);治疗14 d后,两组患者的NIHSS评分均明显降低,ADL评分均明显提高,且观察组患者的NIHSS评分为(4.06±0.93)分,明显低于对照组的(5.82±1.52)分,ADL评分为(76.62±21.13)分,明显高于对照组的(61.03±17.68)分,差异均有统计学意义(P<0.05);观察组患者的总不良反应发生率为2.94%,明显低于对照组的17.65%,差异有统计学意义(P<0.05)。结论丁苯酞软胶囊治疗LSA-BAD型梗死能明显改善患者的神经功能,提高其日常生活能力,并减少不良反应的发生,临床治疗效果显著。

Objective To study the clinical efficacy of butylphthalide soft capsule in the treatment of infarction classified as branch atheromatous disease(BAD)involving the lenticulostriate artery(LSA)territory.Methods A total of 68 patients with infarction classified as BAD involving the LSA territory who were admitted and treated in the Department of Neurology,Xiaolan People's Hospital of Zhongshan from June 2017 to June 2020 were selected as the research objects.According to the random odd and even number method,all patients were divided into the study group and control group,each with 34 patients.The patients in the control group were given conventional treatment,and the patients in the study group were given butylphthalide soft capsule treatment on the basis of conventional treatment in the control group.After 14 days of treatment,the clinical efficacy,the National Institutes of Health Stroke Scale(NIHSS)scores,and the ability of daily living(ADL)scores before and after treatment were compared between the two groups,and the incidence of adverse reactions was compared between the two groups.Results The total effective rate of treatment in the study group was 94.12%,which was significantly higher than 70.59%in the control group(P<0.05);after 14 days of treatment,the NIHSS scores of the two groups were significantly reduced,the ADL scores were significantly improved;the NIHSS score of the patients in the study group was(4.06±0.93)points,which was significantly lower than(5.82±1.52)points of the control group;the ADL score was(76.62±21.13)points,which was significantly higher than(61.03±17.68)points of the control group,with statistically significant differences(P<0.05).The total adverse reaction rate in the study group was 2.94%,which was significantly lower than 17.65%in the control group(P<0.05).Conclusion Butylphthalide soft capsule in the treatment of infarction classified as BAD involving the LSA territory can significantly improve the neurological function of patients,improve their ability of daily living,and reduce the occurrence of adverse reactions,with significant clinical treatment.